Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.65 |
| ▸ | ALPL | P05186 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | XBP1 | P17861 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3823239 | 0.94 | PPARG (0.66) | PPARGALPLCYP3A4KMT2ARAB9A | |
| SCHEMBL3828138 | 0.93 | PPARG (0.64) | PPARGALPLCYP3A4KMT2ARAB9A | |
| SCHEMBL3799880 | 0.92 | PPARG (0.63) | PPARGALPLCYP3A4KMT2ARAB9A | |
| SCHEMBL3821578 | 0.92 | ALPL (0.69) | PPARGALPLCYP3A4KMT2ARAB9A | |
| SCHEMBL3828751 | 0.92 | PPARG (0.62) | PPARGALPLCYP3A4KMT2ARAB9A | |
| SCHEMBL3828191 | 0.91 | PPARG (0.67) | PPARGALPLCYP3A4KMT2ARAB9A | |
| SCHEMBL3830305 | 0.90 | PPARG (0.62) | PPARGALPLCYP3A4KMT2ARAB9A | |
| SCHEMBL14689198 | 0.89 | PPARG (0.63) | PPARGALPLCYP3A4KMT2ARAB9A | |
| SCHEMBL3822556 | 0.88 | PPARG (0.59) | PPARGALPLCYP3A4KMT2ARAB9A | |
| SCHEMBL3826514 | 0.88 | PPARG (0.67) | PPARGALPLCYP3A4KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309786-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2012-12-06 | — | — | US | claimed |
| US-20090247574-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2009-10-01 | — | — | US | claimed |
| EP-2094687-A1 | 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Life Sciences Limited (IN) | 2009-09-02 | — | — | EP | claimed |
| WO-2008035306-A1 | 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-27 | — | — | WO | claimed |
| US-20130040988-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2013-02-14 | — | — | US | disclosed |
| US-20120309786-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2012-12-06 | — | — | US | disclosed |
| US-8269010-B2 | 3-amino-pyridine derivatives for the treatment of metabolic disorders | PIRAMAL HEALTHCARE LIMITED (IN) | 2012-09-18 | — | — | US | disclosed |
| US-20090247574-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2009-10-01 | — | — | US | disclosed |
| EP-2094687-A1 | 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Life Sciences Limited (IN) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008035306-A1 | 3 -AMINO- PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040988-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, ABAT, GOT2 | PPARG 69/4885ALPL 893/4885CYP3A4 118/4885 |
| US-20120309786-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, ABAT, PYGL | PPARG 62/4885ALPL 751/4885CYP3A4 134/4885 |
| US-20090247574-A1 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, ABAT, PDXK | PPARG 91/4885ALPL 1637/4885CYP3A4 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.